Organizations will refer clients for laboratory, preclinical, and clinical projects to each other.
PPD and Lovelace Biomedical and Environmental Research Institute (LBERI) entered into a collaboration focused on future service opportunities for biopharmaceutical and government clients across a range of therapeutic areas.
The organizations plan to refer to one another potential business opportunities for laboratory, preclinical, and clinical-development services that they do not offer to their respective clients. In addition, they intend to work together and jointly bid on select new research projects.
“As demand for preclinical services grows our collaboration with LBERI builds on our strong capabilities and competitive position, particularly in the areas of respiratory, infectious diseases, health outcomes, and epidemiology,” remarks David Grange, CEO of PPD. “This collaboration also enables us to broaden our work with government organizations through LBERI’s existing government relationships.”
Robert Rubin, Ph.D., president and CEO of Lovelace Respiratory Research Institute, of which LBERI is a subsidiary, adds, “Aligning with one of the world’s leading CROs allows us to build on our 65-plus year history of discovery research, public health advancement, and extensive preclinical service offerings.”
